Health
Vaccine news no cure for volatility, warn investors – Sydney Morning Herald
Global sharemarkets are expecting major updates on vaccine approvals in the next two months, but good news won’t counteract market volatility, investors warn.
Amid the uncertainty caused by COVID-19 shutdowns, investors have been particularly sensitive to news – positive or negative – about a potential vaccine.
At the start of July the benchmark S&P/ASX 200 rallied above the 6000 mark, gaining 1.7 per cent on a positive update from Pfizer about its project. On September 9, the local sharemarket dropped more than 2 per cent after the market digested the news that the University of Oxford and AstraZeneca had paused their phase 3 trial after an adve…
Continue Reading
